Format

Send to

Choose Destination
MAbs. 2017 Feb/Mar;9(2):213-230. doi: 10.1080/19420862.2016.1267089. Epub 2016 Dec 8.

Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.

Author information

1
a Department of Antibody Engineering , Genentech, Inc. , South San Francisco , CA , USA.
2
b Department of Protein Chemistry , Genentech, Inc. , South San Francisco , CA , USA.
3
c Department of Translational Oncology , Genentech, Inc. , South San Francisco , CA , USA.
4
d Department of Microchemistry, Proteomics and Lipidomics , Genentech, Inc. , South San Francisco , CA , USA.
5
e Department of Preclinical and Translational Pharmacokinetics , Genentech, Inc. , South San Francisco , CA , USA.
6
f Department of Early Stage Cell Culture , Genentech, Inc. , South San Francisco , CA , USA.
7
g Department of Early Discovery Biochemistry, Genentech, Inc. , South San Francisco , CA , USA.

Abstract

Bispecific IgG production in single host cells has been a much sought-after goal to support the clinical development of these complex molecules. Current routes to single cell production of bispecific IgG include engineering heavy chains for heterodimerization and redesign of Fab arms for selective pairing of cognate heavy and light chains. Here, we describe novel designs to facilitate selective Fab arm assembly in conjunction with previously described knobs-into-holes mutations for preferential heavy chain heterodimerization. The top Fab designs for selective pairing, namely variants v10 and v11, support near quantitative assembly of bispecific IgG in single cells for multiple different antibody pairs as judged by high-resolution mass spectrometry. Single-cell and in vitro-assembled bispecific IgG have comparable physical, in vitro biological and in vivo pharmacokinetics properties. Efficient single-cell production of bispecific IgG was demonstrated for human IgG1, IgG2 and IgG4 thereby allowing the heavy chain isotype to be tailored for specific therapeutic applications. Additionally, a reverse chimeric bispecific IgG2a with humanized variable domains and mouse constant domains was generated for preclinical proof-of-concept studies in mice. Efficient production of a bispecific IgG in stably transfected mammalian (CHO) cells was shown. Individual clones with stable titer and bispecific IgG composition for >120 days were readily identified. Such long-term cell line stability is needed for commercial manufacture of bispecific IgG. The single-cell bispecific IgG designs developed here may be broadly applicable to biotechnology research, including screening bispecific IgG panels, and to support clinical development.

KEYWORDS:

Bispecific antibody; bispecific IgG; orthogonal Fab engineering; single-cell production; stable CHO cell lines

PMID:
27929752
PMCID:
PMC5297516
DOI:
10.1080/19420862.2016.1267089
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center